More than 200 generic drugs FDA-approved for non-cancer indications have shown promise for treating cancer. Due to their long history of safe patient use, low cost, and widespread availability, repurposing of these drugs represents a major opportunity to rapidly improve outcomes for cancer patients and reduce healthcare costs. In many cases, there is already some clinical evidence of efficacy for cancer. Yet a market failure for repurposing off-patent and inexpensive drugs means that these promising cancer treatments are not fully tested or incorporated into common medical practice for cancer use.
Cures Within Reach for Cancer (CWR4C) is a nonprofit startup creating new and affordable cancer treatments by harnessing artificial intelligence (AI) to repurpose generic drugs. We are building the Oncology Repurposing Engine™, an AI-powered decision framework that synthesizes the plethora of scientific and real-world data on non-cancer generics and identifies the most promising therapies to be repurposed for cancer. To enable sustainable patient impact, we are developing new models for funding and conducting clinical validation and for incorporating repurposed therapies into the standard of care.
CWR4C’s Founder and Executive Director is Laura Kleiman. Laura earned a PhD in Computational and Systems Biology from MIT, was an American Cancer Society Postdoctoral Fellow at the Massachusetts General Hospital and Harvard Medical School, and served as Scientific Research Director in the Department of Data Sciences at the Dana-Farber Cancer Institute. Motivated by family and friends fighting cancer, Laura is passionate about collaborating across disciplines and sectors to expand treatment options for cancer patients.
The CWR4C team includes experts in cancer drug development, medical oncology, AI and machine learning, real-world evidence, business and nonprofit management, and patient advocacy. We are located in Boston and are fiscally sponsored by Cures Within Reach. CWR4C has been recognized through awards from MassBio and the Dana-Farber Cancer Institute, and we are currently a finalist in the social impact track of MassChallenge, one of the largest startup accelerators in the world.